You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Article metrics

Article menu

See original article:

Download PDFPDF

XML
Research Article
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

 

Online download statistics by month:

Online download statistics by month: December 2019 to November 2025

AbstractFullPdf
Dec 2019220
Jan 202010101
Feb 2020999920
Mar 2020838333
Apr 2020707013
May 2020838310
Jun 2020474716
Jul 2020474710
Aug 2020535424
Sep 2020787823
Oct 202011011041
Nov 2020505022
Dec 2020575717
Jan 2021858523
Feb 2021666614
Mar 202111211225
Apr 2021979728
May 202135235320
Jun 2021919112
Jul 202110610618
Aug 202196967
Sep 202110610427
Oct 202113113138
Nov 202112212253
Dec 202110410430
Jan 2022939516
Feb 2022818116
Mar 2022858943
Apr 202232336
May 2022636422
Jun 2022687129
Jul 2022717210
Aug 2022707012
Sep 2022828218
Oct 202215015020
Nov 2022859034
Dec 2022797911
Jan 2023919321
Feb 202312813117
Mar 202310010220
Apr 2023495014
May 2023646818
Jun 2023666619
Jul 2023676725
Aug 2023757617
Sep 202376766
Oct 202318918914
Nov 202331631616
Dec 2023959516
Jan 2024747420
Feb 2024626221
Mar 2024828480
Apr 2024626241
May 2024666526
Jun 2024626228
Jul 2024737421
Aug 202453538
Sep 2024414415
Oct 2024868635
Nov 202414314419
Dec 202416817327
Jan 202515515923
Feb 2025505123
Mar 2025808022
Apr 2025919225
May 202520320327
Jun 202513913912
Nov 2025110
Total622362701438